X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 65 filers reported holding X4 PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $9 | -90.4% | 10,092 | -89.4% | 0.00% | – |
| Q4 2022 | $94 | -100.0% | 94,794 | -60.9% | 0.00% | -100.0% |
| Q3 2022 | $414,000 | +98.1% | 242,194 | +12.0% | 0.00% | – |
| Q2 2022 | $209,000 | -31.0% | 216,194 | +24.9% | 0.00% | – |
| Q1 2022 | $303,000 | -3.5% | 173,094 | +26.1% | 0.00% | – |
| Q4 2021 | $314,000 | -50.7% | 137,294 | +14.0% | 0.00% | -100.0% |
| Q3 2021 | $637,000 | -25.1% | 120,394 | -7.9% | 0.00% | 0.0% |
| Q2 2021 | $850,000 | -36.8% | 130,694 | -16.2% | 0.00% | -50.0% |
| Q1 2021 | $1,344,000 | +28.7% | 156,044 | -3.9% | 0.00% | +100.0% |
| Q4 2020 | $1,044,000 | -1.1% | 162,424 | +4.1% | 0.00% | 0.0% |
| Q3 2020 | $1,056,000 | +10.1% | 156,044 | +51.7% | 0.00% | 0.0% |
| Q2 2020 | $959,000 | +78.3% | 102,844 | +91.0% | 0.00% | 0.0% |
| Q1 2020 | $538,000 | -20.6% | 53,844 | -15.0% | 0.00% | 0.0% |
| Q4 2019 | $678,000 | – | 63,344 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,682,000 | 3.48% |
| Sio Capital Management, LLC | 804,597 | $6,928,000 | 1.41% |
| Bain Capital Life Sciences Investors, LLC | 2,119,540 | $18,249,000 | 1.03% |
| SV Health Investors, LLC | 311,490 | $2,682,000 | 1.00% |
| Monashee Investment Management LLC | 574,712 | $4,948,000 | 0.76% |
| Ikarian Capital, LLC | 2,614,988 | $22,515,000 | 0.76% |
| Abingworth LLP | 229,885 | $1,956,000 | 0.68% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,884,000 | 0.67% |
| BVF INC/IL | 1,091,579 | $9,398,000 | 0.35% |
| Endurant Capital Management LP | 151,996 | $1,309,000 | 0.34% |